REGENEREX PHARMA, INC. Research and Development Expense
REGENEREX PHARMA, INC. reported Research and Development Expense of $156.91 thousand for the 9-month period ending 2025-12-31, per its 10-KT filed 2026-08-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-31
- REGENEREX PHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $23.40K, a 34.66% increase year-over-year.
- REGENEREX PHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $136.43K.
- REGENEREX PHARMA, INC. research and development expense for the quarter ending 2025-03-31 was $645.10K.
- REGENEREX PHARMA, INC. research and development expense for the quarter ending 2024-12-31 was $17.38K.
- REGENEREX PHARMA, INC. research and development expense for fiscal 2025 was $662.48K, a 72.40% decline from fiscal 2024.
- REGENEREX PHARMA, INC. research and development expense for fiscal 2024 was $2.40M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.40K derived: 10-KT 9 month − 10-Q 6 month · filed 2026-08-31 | $159.84K derived: sum of 2 quarters · filed 2026-08-31 | $156.91K 10-KT · filed 2026-08-31 | |
| 2025-09-30 | $136.43K 10-Q · filed 2025-11-17 | $133.51K 10-Q · filed 2025-11-17 | ||
| 2025-03-31 | $645.10K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-08-31 | $662.48K derived: sum of 2 quarters · filed 2026-08-31 | $662.48K 10-KT · filed 2026-08-31 | |
| 2024-12-31 | $17.38K 10-Q · filed 2025-02-07 | $17.38K 10-Q · filed 2025-02-07 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | $0.00 derived: sum of 2 quarters · filed 2025-06-30 | $2.40M derived: sum of 3 quarters · filed 2025-06-30 | $2.40M 10-K · filed 2025-06-30 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-07 | $2.40M derived: sum of 2 quarters · filed 2025-02-07 | $2.40M 10-Q · filed 2025-02-07 | |
| 2023-09-30 | $2.40M 10-Q · filed 2024-11-04 | $2.40M 10-Q · filed 2024-11-04 | ||
| 2018-12-31 | $300.00 10-Q · filed 2020-02-10 | $300.00 10-Q · filed 2020-02-10 |